Florey researchers unlock how to use mRNA to target Alzheimer’s disease
Posted: 15 April 2024 Scientists at The Florey have developed an mRNA technology approach to target the toxic protein tau, which builds up in patients with Alzheimer’s disease and other dementias. To date, mRNA has been predominantly used…
Wound healing is a billion dollar drain on the health system – this discovery hopes to plug it
Posted: 15 April 2024 Scientists have uncovered a key step in the wound healing process that becomes disabled in diseases like diabetes and ageing, contributing to a global healthcare cost of managing poorly healing wounds exceeding $250 billion…
Risk prediction using our genes and gut bacteria can improve early detection of diseases like type 2 diabetes
Posted: 15 April 2024 A new study has shown that risk scores based on our genes and gut bacteria can improve the prediction of diseases such as type 2 diabetes and prostate cancer over traditional risk factors alone.…
Australia’s first purpose-built facility to deliver human challenge trials launches in Melbourne
Posted: 15 April 2024 Australia’s first clinical trial facility specifically commissioned to deliver human challenge trials, Doherty Clinical Trials Ltd, was launched today in East Melbourne by The Honourable Ben Carroll MP Minister for Medical Research and Professor…
Monash’s Parkville campus appoints new head of medicinal chemistry
Posted: 15 April 2024 The Monash Institute of Pharmaceutical Sciences (MIPS), which sits within Monash’s world-leading Faculty of Pharmacy and Pharmaceutical Sciences, has appointed Professor Martin Scanlon as the new Theme Leader for Medicinal Chemistry. MIPS is renowned for its…
Florey discovery could help reduce global shortage of diabetes and weight loss drug semaglutide
Posted: 15 April 2024 Semaglutide is part of the glucagon-like peptide-1 (GLP-1) receptor targeting family of peptide drugs, which are mainly used to treat diabetes but are difficult and expensive to make. An international team of researchers led…
Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication
Posted: 11 April 2024 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health, is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study…
Positive preclinical data for deoxymabs in vasculitis
Posted: 11 April 2024 Patrys Limited a therapeutic antibody development company, is delighted to announce that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis were…
Update on Amplia’s Accent Trial in Pancreatic Cancer
Posted: 11 April 2024 Amplia Therapeutics limited is pleased to provide an update on our Phase 1b/2a trial (the ACCENT trial) of narmafotinib in combination with standard-of-care chemotherapy gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer.…
Clarity launches $121 million fully underwritten equity raising
Posted: 11 April 2024 Clarity Pharmaceuticals (ASX:CU6) (“Clarity” or “Company”) a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce a fully…
VivaZome Therapeutics and La Trobe University to collaborate on development of extracellular vesicle therapy for treatment of stroke
Posted: 11 April 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke…
Cartherics enters into Collaborative Research Agreement with TiCARos
Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess…
